For the first time, two gene therapy programs for Rett syndrome have reached late-stage clinical trials. Both have received FDA Breakthrough Therapy designation, and both finished dosing their registrational trials in June 2026, so neither is enrolling new patients right now. First results are expected in 2027. For families who have been waiting years for something beyond symptom management, this is the most significant shift in the treatment landscape since trofinetide (Daybue) was approved in 2023.
This guide breaks down what the two gene therapy programs are, how they differ, what the clinical data has shown so far, and what families should think about when it comes to eligibility. The goal is to give caregivers a clear picture of where things stand in 2026, written in plain language.
The Two MECP2 Gene Therapy Programs in Clinical Trials
Both programs aim to deliver a working copy of the MECP2 gene into the brain. That is the core idea behind gene therapy for Rett: if the disease is caused by a broken or missing gene, put a functional version of that gene where it needs to be. But the two companies, Neurogene and Taysha Gene Therapies, are going about it differently.
Neurogene's NGN-401
NGN-401 is delivered through an intracerebroventricular (ICV) injection, meaning the gene therapy goes directly into the fluid-filled spaces of the brain. Neurogene designed this route to get the broadest distribution across the central nervous system. NGN-401 is also the only clinical candidate that delivers the full-length human MECP2 gene, paired with Neurogene's EXACT transgene regulation technology, which is intended to control how much MeCP2 protein each cell produces.
That regulation piece matters. One of the unique challenges with Rett gene therapy is that too much MeCP2 is also harmful. A condition called MECP2 duplication syndrome causes its own set of serious neurological problems. So any gene therapy has to get the dose right at the cellular level, not just the injection level.
Neurogene's Phase 1/2 trial showed clinically meaningful improvements in the low-dose cohort (1E15 vector genomes). According to the company, all pediatric participants gained developmental milestones or experienced functional gains, with improvements on the Rett Syndrome Behavior Questionnaire (RSBQ) ranging from 28 to 52% from baseline. The FDA granted Breakthrough Therapy designation in February 2026 based on this data.
The registrational trial, called Embolden, began dosing in late 2025 and finished dosing in June 2026 with 25 participants treated. Neurogene expects topline data in the second half of 2027.
Taysha's TSHA-102
TSHA-102 takes a different delivery route. It is administered through a lumbar intrathecal injection, which goes into the spinal fluid rather than directly into the brain ventricles. The therapy uses an AAV9 vector and includes a self-regulating element called miRARE (miRNA-Responsive Auto-Regulatory Element) that is designed to prevent MECP2 overexpression on a cell-by-cell basis.
In Part A of the REVEAL Phase 1/2 trial, Taysha reported that 100% of patients gained or regained at least one developmental milestone after treatment. The high dose consistently outperformed the low dose, and there were no treatment-related serious adverse events or dose-limiting toxicities across 10 patients aged 6 to 21.
The FDA also granted Breakthrough Therapy designation to TSHA-102. The pivotal Part B trial began dosing its first patient in Q4 2025. Taysha completed dosing of 17 patients in June 2026 and expects topline data in the first half of 2027.
NGN-401 vs. TSHA-102: Key Differences for Families
The biggest practical differences for families are the delivery method, the age ranges being studied, and the specific eligibility criteria around medications and genetic confirmation.
NGN-401 uses intracerebroventricular delivery (into the brain's ventricles), while TSHA-102 uses intrathecal delivery (into the spinal fluid). Both are one-time treatments. Both require a confirmed disease-causing MECP2 mutation. Both have regulation technology to prevent overexpression. And both have received the same FDA Breakthrough Therapy designation.
What is different is the safety history. NGN-401 had a fatal adverse event at the higher dose level, which led to that arm being dropped. TSHA-102 has not reported any treatment-related serious adverse events across its Phase 1/2 program. That does not mean one is categorically safer than the other, since the programs use different doses, vectors, and delivery routes, but it is context that families should have when evaluating their options.
Does Your Child's MECP2 Mutation Affect Eligibility?
Yes. Both programs require genetic confirmation of a disease-causing MECP2 mutation. But beyond that basic requirement, the specific mutation your child carries can influence how severe the condition is and potentially which trials are the best fit.
More than 800 different disease-causing MECP2 mutations have been catalogued, but according to the Nature Scientific Data catalogue, eight recurrent hotspot mutations account for roughly 46 to 47% of all Rett cases: R106W, R133C, T158M, R168X, R255X, R270X, R294X, and R306C. Research has shown that truncating mutations like R255X and R270X tend to be associated with more severe disease, while certain mutations like R133C (missense) and R294X (a late truncation that preserves most of the functional protein) are often linked to a milder course.
One thing that families sometimes find confusing is the distinction between classic Rett syndrome and conditions that used to be grouped under "atypical Rett." Specifically, CDKL5 deficiency disorder and FOXG1 syndrome are now recognized as separate genetic conditions with their own clinical features and their own trial pipelines. If your child has been diagnosed with one of these, the MECP2 gene therapy trials would not apply, but there may be other studies worth exploring.
Rett Syndrome Medications and Clinical Trial Eligibility
This is probably the most common question families ask. The short answer is: it depends on the specific trial and the specific medication. But there are some general patterns.
Since 60 to 80% of Rett patients have epilepsy according to research published in Brain and Behavior, most children are on at least one anti-seizure medication. The good news is that most Rett trials do not require stopping seizure medications. What they do require is stability, usually meaning no changes to the type or dose for a set period before enrollment. Gene therapy trials like NGN-401 have required a stable anti-seizure regimen for at least 12 weeks.
Trofinetide (Daybue) is a more complicated question. Since Daybue is the only FDA-approved Rett-specific treatment, many families are already on it. Some gene therapy and novel mechanism trials may exclude patients currently taking Daybue or require a washout period before enrollment. This makes sense from a research design perspective, since investigators need to measure the effect of the new therapy without another active treatment confounding the results.
Behavioral medications like risperidone (Risperdal) or aripiprazole (Abilify) can also affect eligibility. Trials that measure behavioral or cognitive outcomes may exclude antipsychotics because they can make it harder to tell what improvement came from the study drug versus the existing medication.
Trial Friend's Rett syndrome page includes a medication conflict checker that can help you screen active trials against your child's current prescriptions. It is not a substitute for talking to the study team, but it can give you a quick sense of which trials may or may not work with your child's current regimen.
[Trofinetide](/drugs/trofinetide) (Daybue) and Gene Therapy Trial Eligibility
Daybue (trofinetide), approved in March 2023, was the first FDA-approved treatment specifically for Rett syndrome. It is a synthetic analog of glycine-proline-glutamate (GPE), the amino-terminal tripeptide of IGF-1, that addresses neuroinflammation and synaptic dysfunction. It is not a cure, and it does not fix the underlying MECP2 mutation, but clinical trials showed meaningful improvements in caregiver-reported behavioral symptoms.
The real-world experience has been mixed. Diarrhea is a significant side effect, affecting roughly 85% of patients in clinical studies, and about 15% of patients discontinued treatment because of it. Acadia Pharmaceuticals, the company behind Daybue, has since developed diarrhea management protocols and released a new powder formulation called Daybue Stix (approved December 2025) that is dye-free and preservative-free. Data from the LOTUS long-term follow-up study showed that about 70% of patients who start Daybue have continued treatment for at least six months.
For families weighing Daybue against a gene therapy trial, it is worth having a direct conversation with your child's neurologist. In some cases, being on Daybue may affect trial eligibility. In others, a washout period may be all that is needed.
One email when Rett Syndrome trials change or an FDA decision lands. No newsletter, no spam.
Questions to Ask Your Neurologist About Rett Trials
If you are considering a gene therapy trial for your child, here are some questions that can help guide the conversation with your neurologist or geneticist:
Does my child's specific MECP2 mutation affect which trials she qualifies for? Can she participate while continuing her current seizure medications? Would she need to stop Daybue, and if so, for how long? What is the difference between the ICV delivery used by NGN-401 and the intrathecal delivery used by TSHA-102? How would trial participation affect her current therapy schedule, including physical therapy, occupational therapy, and speech? Are there trials designed specifically for her age group?
The International Rett Syndrome Foundation maintains an updated research pipeline that tracks all active and upcoming Rett trials. The Rett Syndrome Research Trust is another excellent resource for families following the science.
The Outlook for Rett Syndrome Gene Therapy in 2026
There is real momentum in Rett research right now, and the gene therapy results so far are genuinely encouraging. But it is also important to be realistic about where we are. These are still investigational therapies. Both registrational trials have finished dosing, with first results expected in 2027, and any approval would come after that. The safety profile of brain-directed AAV gene therapy is still being understood, and the high-dose death in the NGN-401 trial is a reminder that this work carries real risk alongside real promise.
For families, the most important thing right now is to stay informed and be ready. Make sure your child has a confirmed MECP2 mutation through genetic testing. Talk to your neurologist about whether trial participation makes sense for your child's specific situation. And keep track of what medications your child is on, because that information will matter when eligibility questions come up.
“The families I talk to are not looking for miracles. They just want to know what is real, what is next, and what they can do right now.”
A Rett caregiver on navigating clinical trials
You can explore all active Rett syndrome clinical trials on Trial Friend, including eligibility criteria in plain English, medication conflict checking, and the ability to filter by trial phase and recruitment status.